SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS® Test at 2021 ASCO Annual Meeting
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American Society of Clinical Oncology annual meeting, to be held virtually June 4-8, 2021.
Details related to the poster presentation are as follows:
About PARIS® Test
About SEngine Precision Medicine
Key Tools of the IoT Security Trade